Description: Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Home Page: www.atarabio.com
ATRA Technical Analysis
611 Gateway Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 278 8930
Officers
| Name | Title |
|---|---|
| Dr. Pascal Touchon D.V.M. | Pres, CEO & Director |
| Mr. Utpal Koppikar M.B.A. | Exec. VP & CFO |
| Mr. K. Amar Murugan | Sr. VP & Gen. Counsel |
| Dr. Jakob Dupont M.D. | Exec. VP and Global Head of R&D |
| Ms. Charlene Banard | Chief Technical Officer |
| Dr. Anhco Nguyen | Chief Scientific Officer |
| Eric Hyllengren | VP of Investor Relations & Fin. |
| Kerry Beth Daly | Head of Corp. Communications |
| Ms. Amie Krause | Chief People Officer |
| Mr. Joseph Newell | Exec. VP |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9674 |
| Price-to-Sales TTM: | 4.5385 |
| IPO Date: | 2014-10-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 340 |